Loading
If this is the first time anyone has visited this substance, we may be fetching live data from TGA Product Information, PBS, and state framework sources — that can take up to a minute. Cached substances load in a second or two.
Curated subset. The full adverse-effect list is in the TGA Product Information; click any citation above to open it.
“Talquetamab (also known as JNJ-64407564) is a humanised immunoglobulin G4 proline, alanine, alanine (IgG4 PAA) bispecific antibody directed against GPRC5D on multiple myeloma cells and the CD3 receptor on T Cells.”
“The median terminal phase half-life based on the post hoc parameters of all SC population (N=392) was 7.56 days at initial treatment, and 12.2 days at steady state.”
Working under the parallel aged-care framework? Aged-care equivalent →
“Talquetamab causes release of cytokines (see section 5.1 PHARMACODYNAMIC PROPERTIES - Pharmacodynamic Properties – Pharmacodynamic effects) that may suppress activity of cytochrome P450 (CYP) enzymes, potentially resulting in increased exposure of CYP substrates.”